Four serum neurofilament light chain tests show high accuracy in diagnosing ALS and predicting its progression, new research suggests.

Lorem, a nonprofit foundation, today announced that nine patients with an ultra-rare type of amyotrophic lateral sclerosis (ALS) have been treated during the first year of a multi-year grant from the ...

ALS Canada has named 39 Canadians to receive the King Charles III Coronation Medal for their efforts into research and advocacy for ALS.

Eight years after receiving a life-shattering diagnosis, a New Jersey mother credits an “amazing” new drug for stopping her ...

As other gene editing programs fold or get sold, Arbor Biotechnologies has secured $73.9 million to advance its lead liver-targeting gene therapy into human trials. | As other gene editing programs ...

Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a ...

Series C led by ARCH Venture Partners and TCGX with significant participation from existing and new investors Financing extends Arbor’s cash runway into 2027 and supports the clinical development of ...

The round will fund a “one-and-done” treatment for a rare kidney condition that its CEO says can address concerns patients ...

The gene therapy world is in turmoil, but Arbor, armed with more than a billion dollars in partnerships and raises, is going forward.

Equities research analysts at Wedbush reduced their Q1 2025 earnings per share estimates for shares of Voyager Therapeutics ...

Neurodegenerative diseases represent a significant challenge in medical science, impacting millions globally. Despite advancements in diagnostic technology, ...

The firm will use the funds to develop its lead candidate in primary hyperoxaluria type 1 and other pipeline products in liver and CNS disorders.